Zydus Lifesciences Limited (including its subsidiaries/affiliates hereafter referred to as “Zydus”) a discovery-driven, global lifesciences company announced the appointment of Punit Patel as President and Chief Executive Officer, Americas. He will be responsible for the business operations of all Zydus entities in North America which include generics, injectables and specialty business, rare and orphan disease…
Zydus, an innovation driven global pharma major and TLC, a specialty pharmaceutical company in Taiwan, announced the signing of a license supply and commercialization agreement to commercialize AmphoTLC (Amphotericin B Liposome for Injection 50mg) in India. AmphoTLC is a critical drug to treat Mucormycosis or Black Fungus in India. Under the terms of the agreement,…
Zydus, a leading discovery based global pharmaceutical company announced that it has received approval from the regulatory authority of Mexico, COFEPRIS, for its one of its lead research candidate Desidustat to be tested in the management of COVID-19. Clinical and regulatory development of Desidustat in COVID-19 is being executed in Mexico by Avant Santé Research…
Zydus, an innovation-driven global pharmaceutical company, announced that it’s plasmid DNA vaccine candidate for COVID-19 (ZyCoV-D) developed indigenously at its Vaccine Technology Centre in Ahmedabad, India has successfully completed the preclinical phase and has now received permission from the Drug Controller General of India – Central Drugs Standard Control Organisation (CDSCO) to initiate Phase I/II…
Zydus Cadila, an innovation-driven global healthcare company, announced that it has signed a non-exclusive licensing agreement with Gilead Sciences Inc., for the manufacturing and distribution of Remdesivir, the investigational drug, which has been issued an Emergency Use Authorization by the U.S. Food and Drug Administration (FDA) to treat patients suffering from severe symptoms of Novel…
Zydus, a discovery based global pharmaceutical company, announced that it has entered into a licensing agreement with China Medical System Holdings Limited for the development and commercialization of Desidustat, a novel oral HlF-PH inhibitor for the treatment of anemia in patients with Chronic Kidney Disease (CKD) not—on—dialysis and for the treatment of Anemia CKD patients…